Why the transdermal delivery of selegiline (6 Mg/24 Hr) obviates the need for a dietary restriction on tyramine

Journal of Psychiatric Practice

Volumn 12, Issue 3, 2006, Pages 168-172

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; TYRAMINE;

BRAIN CORTEX; CLINICAL TRIAL; DEPRESSION; DIET RESTRICTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DUODENUM; ENZYME INACTIVATION; ENZYME INHIBITION; GUINEA PIG; HUMAN; HYPERTENSIVE CRISIS; LIVER; NONHUMAN; REVIEW;

ADMINISTRATION, CUTANEOUS; ANIMALS; DEPRESSIVE DISORDER; DIET; FOOD-DRUG INTERACTIONS; GUINEA PIGS; HUMANS; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; TYRAMINE;

EID: 33747822008     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200605000-00006     Document Type: Review

References (21)

1. Bristol-Myers Squibb. EMSAM package insert. February 2006. www.bms.com/products/data.
2. Magyar K, Palfi M, Tabi T, et al.Pharmacological aspects of (-)-deprenyl. Curr Med Chem 2004;11:2017-31.
3. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-37.
4. McGrath PJ, Stewart JW, Harrison WM, et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol 1992;12:197-202.
5. McGrath PJ, Stewart JW, Quitkin FM. The use of monoamine oxidase inhibitors for treating atypical depression. Psychiatr Ann 2001;31:371-5.
6. Nolen WA, Haffmans PM, Bouvy PF, et al. Monoamine oxidase inhibitors in resistant major depression. J Affect Disord 1993;28:189-97.
7. Nolen WA, Van De Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988;78:676-83.
8. Henkel V, Mergl R, Allgaier AK, et al. Treatment of depression with atypical features: A meta-analytic approach. Psychiatry Res 2006;141:89-101.
9. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression: A retrospective study. J Affect Disord 2005;89:183-8.
10. Birkenhager TK, van den Broek WW, Mulder PG, et al. Efficacy and tolerability of tranylcypromine versus phenelzine: A double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry 2004;65:1505-10.
11. Fiedorowicz JG, Swartz KL.The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 2004;10:239-48.
12. Janicak PG, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
13. Kennedy SH, Holt A, Baker GB. Monoamine oxidase inhibitors. In: Preskorn SH, Feighner JP, Stanga CY, et al., eds. Antidepressants: Past, present and future. Berlin: Springer; 2004:209-39.
14. Preskorn SH. The case studies section. Series of columns published in the Journal of Psychiatric Practice (www.preskorn.com/column1.html).
15. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, et al., eds. Antidepressants: Past, present and future. Berlin: Springer; 2004:87-114.
16. Gal S, Zheng H, Fridkin M, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 2005;95:79-88.
17. De Colibus L, Li M, Binda C, et al. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci U S A 2005;102:12684-9.
18. Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: A potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24:1295-305.
19. Lang W, Masucci JA, Caldwell GW, et al. Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: Application of biomarkers in drug discovery. Anal Biochem 2004;333:79-87.
20. Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: Meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004;329:593.
21. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003;55: 27-34.